November 8, 2024, according to Japanese media news, Japan's Kobayashi Pharmaceutical Company released that  it has been affected by the incident of  health care products containing red currant ingredient causing health damage to consumers, and that the related losses have accumulated to 10.1 billion yen (about 475 million yuan) due to the recall of the products as well as compensations, among other reasons. At the same time released the first three quarters of fiscal year 2024 (January to September) consolidated financial results show that net profit decreased by 65.5% year-on-year to 5.3 billion yen, sales decreased by 3.9% to 114.4 billion yen.